Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nimenrix + Infanrix hexa
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Nimenrix + Infanrix hexa refers to the co-administration of two pediatric vaccines developed by GSK: Nimenrix, a quadrivalent meningococcal conjugate vaccine, and Infanrix hexa, a hexavalent combination vaccine. Infanrix hexa is indicated for primary and booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). Nimenrix provides active immunization against invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, W-135, and Y. The co-administration of these vaccines has been evaluated in Phase 3 clinical trials to demonstrate non-inferiority in immunogenicity and safety compared to individual administration, aiming to streamline infant and toddler immunization schedules by reducing the number of required injections.
- Other names
- Infanrix hexa + Nimenrix
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)PRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)PRN (Pertactin)TT (Tetanus toxoid)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)
Beyond the preview
Go deeper on Nimenrix + Infanrix hexa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nimenrix + Infanrix hexa.